Isoniazid + RIFAPENTINE for latent tuberculosis

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 1 trial. Early trial in people, checking safety. As of 19 Nov 2026, from 2 registered trials.

Why this status

  1. 16 Nov 2021: Trial registered, NCT05122026
  2. 17 Jan 2024: Trial started, NCT05122026
  3. 15 Aug 2025: Trial registered, NCT07124559
  4. 28 Sep 2026: Trial started, NCT07124559

The trials

NCT05122026: Safety and Tolerability of 1 Month Daily (1HP) and 3 Months Weekly (3HP) Isoniazid and Rifapentine With Pharmacokinetics of Dolutegravir (DTG) in Pregnant People With HIV

State
Under way
Phase
Phase 1 and Phase 2
People
252 planned
Started
17 Jan 2024
Primary completion
24 Oct 2025
Arms
Arm 1: One month of daily isoniazid and rifapentine (4 weeks), Arm 2: Three months of once-weekly isoniazid and rifapentine (12 weeks)
Results
None posted
  1. 16 Nov 2021: Trial registered
  2. 17 Jan 2024: Trial started

NCT07124559: A Study of Daily Rifapentine Combined With Isoniazid (1HP) for Tuberculosis Prevention in Children Less Than 13 Years of Age With and Without HIV

State
Under way
Phase
Phase 1 and Phase 2
People
144 planned
Started
28 Sep 2026
Primary completion
26 Jun 2028
Arms
Cohort 1: Children living without HIV
Results
None posted
  1. 15 Aug 2025: Trial registered
  2. 28 Sep 2026: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 1 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.